EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study

Anne-Kristina Mercier iD, Abigail K Kois, Deeyen Karsanji iD, Richard Baldry iD, Filip Birve iD, Maria Hedwall, Oleksandr Molodetskyi iD, Michael Gillen

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Anne-Kristina Mercier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Ethinyl Estradiol, Levonorgestrel, Drug Interactions, Contraceptives, Oral, Combined. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endothelin A receptor antagonist zibotentan, combined with the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin, is being investigated for the treatment of chronic kidney disease with high proteinuria. To allow women of childbearing potential access to this treatment, highly effective contraception is required and drug interactions compromising contraception reliability must be avoided. This study investigated the risk of pharmacokinetic (PK) interaction between zibotentan and the contraceptives ethinyl estradiol and levonorgestrel. A single‐sequence, within‐participant comparison study was conducted in 24 healthy women of non‐childbearing potential, comparing the PK of ethinyl estradiol/levonorgestrel alone and with zibotentan. Single oral doses of 0.06 mg ethinyl estradiol/0.3 mg levonorgestrel were administered on Days 1 and 15; zibotentan 10 mg was dosed orally, once‐daily through Days 6–19. PK profiles were determined and ethinyl estradiol/levonorgestrel PK was compared between Day 1 and 15 based on geometric least‐squares mean ratios of PK parameters, including maximum observed concentration ( C max ) and area under the plasma concentration–time curve from zero to infinity (AUC inf ). Co‐administration with zibotentan did not affect ethinyl estradiol PK (geometric mean ratio [90% confidence interval] C max 1.05 [0.99–1.11], AUC inf 1.00 [0.96–1.05]), while a weak interaction (increased exposure) was observed for levonorgestrel ( C max 1.12 [1.02–1.23], AUC inf 1.30 [1.21–1.39]), which was regarded as without clinical relevance. Plasma exposure of ethinyl estradiol/levonorgestrel was not reduced by multiple‐dose zibotentan. In conclusion, contraception containing ethinyl estradiol/levonorgestrel is regarded possible under zibotentan‐containing treatments. This expands choices for women of childbearing potential, supporting diversity in the ZENITH High Proteinuria trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ethinyl EstradiolLevonorgestrelDrug InteractionsContraceptives, Oral, CombinedHumansFemaleAdultYoung AdultDrug CombinationsEndothelin A Receptor AntagonistsArea Under Curve

Substanzen

Ethinyl EstradiolLevonorgestrelethinyl estradiol, levonorgestrel drug combinationContraceptives, Oral, CombinedDrug CombinationsEndothelin A Receptor Antagonists

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Biometrics, Late-Stage Development, Cardiovascular, Renal and Metabolism, R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical, Late-Stage Development, Cardiovascular, Renal and Metabolism, R&D, AstraZeneca, Gothenburg, Sweden.
  • Global Patient Safety BioPharmaceuticals, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Anne-Kristina Mercier, Deeyen Karsanji, Richard Baldry, Filip Birve, Oleksandr Molodetskyi

Zitieren

APA

Mercier, A. K., Kois, A. K., Karsanji, D., Baldry, R., Birve, F., Hedwall, M., Molodetskyi, O., & Gillen, M. (2024). Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3280

Vancouver

Mercier AK, Kois AK, Karsanji D, Baldry R, Birve F, Hedwall M, et al. Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3280

BibTeX
@article{Mercier2024,
  author = {Mercier, Anne-Kristina and Kois, Abigail K and Karsanji, Deeyen and Baldry, Richard and Birve, Filip and Hedwall, Maria and Molodetskyi, Oleksandr and Gillen, Michael},
  title = {Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3280}
}
Kostenlos starten →